Abstract
An allogeneic tumor cell vaccine should display a natural immunogenicity that allows the stimulation of tumor-reactive effector cells in patients. Furthermore, the vaccine should express antigens that are shared by many tumors to which patients are not tolerant. A variety of tumor peptides should be presented by different HLA-molecules due to limited MHC matching with recipients and last but not least, the vaccine should have a strong growth potential in vitroto allow adequate amounts of vaccine to be generated for long-term usage. In vitro and in situ studies with the renal cell carcinoma cell line RCC-26 demonstrate: (1) RCC-26 can induce complex allospecific responses through direct priming; (2) RCC-26 can not only reactivate cytotoxic T lymphocytes (CTL) of a memory phenotype but they also can induce de novo tumor-antigen associated responses in normal donors; (3) these cells present epitopes restricted by several MHC molecules, allowing the vaccination of patients matched for different HLA alleles; and (4) they stimulate HLA-A*0201-restricted T cells bearing characteristic T cell receptors (TCR). Thus, in addition to using limiting dilution killer and ELISPOT assays, molecular tracking of a tumor-specific TCR can be used to judge the development of antitumor reactivity and vaccine efficiency. Bone Marrow Transplantation (2000) 25, Suppl. 2, S83–S87.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pohla, H., Frankenberger, B., Stadlbauer, B. et al. Allogeneic vaccination for renal cell carcinoma: development and monitoring. Bone Marrow Transplant 25 (Suppl 2), S83–S87 (2000). https://doi.org/10.1038/sj.bmt.1702362
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1702362
Keywords
This article is cited by
-
Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study
Gene Therapy (2011)
-
The intracellular detection of MIP-1beta enhances the capacity to detect IFN-gamma mediated HIV-1-specific CD8 T-cell responses in a flow cytometric setting providing a sensitive alternative to the ELISPOT
AIDS Research and Therapy (2008)
-
Generation of clinical grade dendritic cells with capacity to produce biologically active IL-12p70
Journal of Translational Medicine (2007)
-
The cellular and molecular basis of natural antitumor immunity in renal cell carcinoma patients
Der Urologe (2004)
-
Adoptive tumor therapy with T lymphocytes enriched through an IFN-γ capture assay
Nature Medicine (2001)